Contrasting Prognostic Effects of Tumor-Infiltrating Lymphocyte Density in Cardia and Non-cardia Gastric Adenocarcinomas by 신수진 et al.
190https://jgc-online.org
ABSTRACT
Purpose: This study sought to investigate the prognostic significance of tumor-infiltrating 
lymphocytes (TILs) in relation to tumor location within the stomach.
Materials and Methods: The densities and prognostic significance of TIL subsets were 
evaluated in 542 gastric cancer patients who underwent gastrectomy. Immunohistochemical 
staining for CD3, CD4, CD8, forkhead/winged helix transcription factor (Foxp3), and 
granzyme B was performed.
Results: Cardia cancer was associated with significantly lower densities of CD8 T-cells and 
higher densities of Foxp3 and granzyme B T-cells than non-cardia tumors. Multivariate 
analysis showed that advanced age (hazard ratio [HR], 1.023; 95% confidence interval [CI], 
1.006–1.040), advanced T classification (HR, 2.029; 95% CI, 1.106–3.721), lymph node 
metastasis (HR, 3.319; 95% CI, 1.947–5.658), low CD3 expression (HR, 0.997; 95% CI, 0.994–
0.999), and a high Foxp3/CD4 ratio (HR, 1.007; 95% CI, 1.001–1.012) were independent 
predictors of poor overall survival in cardia cancer patients. In non-cardia cancer patients, 
total gastrectomy (HR, 2.147; 95% CI, 1.507–3.059), advanced T classification (HR, 2.158; 
95% CI, 1.425–3.266), lymph node metastasis (HR, 1.854; 95% CI, 1.250–2.750), and a low 
Foxp3/CD4 ratio (HR, 0.978; 95% CI, 0.959–0.997) were poor prognostic factors for survival.
Conclusions: The densities and prognostic effects of TILs differed in relation to the location 
of tumors within the stomach. The contrasting prognostic effects of Foxp3/CD4 ratio in 
cardia and non-cardia gastric cancer patients suggests that clinicians ought to consider 
tumor location when determining treatment strategies.
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INTRODUCTION
Gastric cancer is a common cancer and a leading cause of cancer-related deaths worldwide 
[1]. Although staging remains the best tool to determine the prognosis and adjuvant 
treatment strategy for gastric cancer patients, outcomes can differ between individuals 
with the same disease stage. Studies have shown that prognosis can be influenced by 
both intrinsic tumor cell characteristics and tumor-associated factors, such as the tumor 
microenvironment and host immune status [2-4]. Tumor-infiltrating lymphocytes (TILs) are 
known to be prognostic factors in solid organ cancers, including gastric cancer [5,6], while 
regulatory T-cells are thought to induce tolerance to altered self-antigens, resulting in an 
immune response that is deleterious to the host [7].
While some studies have shown regulatory T-cells to be associated with poor prognoses in 
patients with gastric cancer [6,8-10], others have reported that regulatory T-cell expression 
is associated with a favorable prognosis [11,12]. It is possible that disregarding the tumor 
location during risk assessment could account for the disparate findings between these studies 
[8,9]. Indeed, recent studies have documented distinct molecular and pathophysiologic 
mechanisms of carcinogenesis in cardia and non-cardia cancers [13,14]. Cardia cancers have 
been associated with gastroesophageal reflux [15,16] and obesity [15,17]; in contrast, non-
cardia cancers have been associated with decreased acidity [18,19]. Such findings suggest 
that a single factor such as acidity can exert opposing effects on carcinogenesis depending 
on the anatomical location of the tumor. Furthermore, different staging systems are used to 
assess cardia and non-cardia cancers (esophageal cancer and stomach cancer, respectively) 
[20,21]. Therefore, we sought to determine whether immune responses to gastric cancer differ 
according to tumor location (cardia and non-cardia regions).
This study aimed to characterize and evaluate the prognostic effects of CD3+, CD4+, CD8+, 
forkhead/winged helix transcription factor (Foxp3)+, and granzyme B (GZB)+ T-cells in 
patients with gastric cancer according to the location of the tumor within the stomach.
MATERIALS AND METHODS
Study design and patients
We performed a retrospective analysis of 542 gastric cancer patients who underwent 
gastrectomy at Severance Hospital between September 1996 and June 2011. Cardia cancer was 
defined as a lesion(s) with an epicenter located within 5 cm of the esophagogastric junction 
[20,21]. The incidence of cardia cancer is low in Korea; therefore, we included a higher 
number of cardia cancer patients in the study to obtain a comparable dataset (cardia: non-
cardia = 2:3). The median follow-up duration was 95 months (interquartile range: 78 months), 
and the final follow-up date was February 28, 2018. Patients with a history of other primary 
cancers and those who died of surgery-related causes were excluded; patients whose paraffin 
blocks were unsuitable for immunohistochemical staining and those who had missing or 
unclear information on the longitudinal location of their tumors were also excluded. Staging 
was performed according to the American Joint Committee on Cancer 8th Edition [21]. 
Patients with stage II/III cancer were prescribed 5-fluorouracil-based adjuvant chemotherapy, 
while those with stage IV cancer received palliative chemotherapy with best supportive care. 
Patients underwent follow-up evaluations every 3 months for 1 year, every 6 months for 2 
years, and annually thereafter for the duration of the scheduled follow-up period. This study 
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was approved by the Yonsei Institutional Review Board (4-2017-0753), and the requirement for 
informed consent was waived because of the retrospective design of the study.
TILs
Immunohistochemical (IHC) staining and quantification of TILs were performed as 
previously described [6]. Briefly, IHC staining was performed on paraffin-embedded cancer 
tissue sections that had been serially sectioned at a thickness of 4 mm after hematoxylin 
and eosin staining. The sections were deparaffinized, rehydrated, and treated for antigen 
retrieval, after which they were incubated for 60 min at room temperature with primary 
monoclonal antibodies against the following antigens (Fig. 1): CD3 (total T lymphocytes, 
1:100, Labvision Corporation, Fremont, CA, USA), CD4 (helper T lymphocytes, 1:100, 
Novocastra, Newcastle upon Tyne, UK), CD8 (cytotoxic T lymphocytes, 1:100, Novocastra), 
Foxp3 (regulatory T-cells, 1:100, Abcam, Cambridge, UK), and GZB (activated cytotoxic T 
lymphocytes, 1:100, Labvision Corporation). Sections were then incubated with horseradish 
peroxidase-conjugated secondary antibodies, developed with diaminobenzidine, and 
counterstained with hematoxylin.
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Fig. 1. Representative images of CD3, CD4, CD8, Foxp3, and granzyme B staining in gastric adenocarcinoma 
specimens. Immunohistochemical staining for (A) CD3 (T lymphocytes), (B) CD4 (helper T lymphocytes), (C) CD8 
(cytotoxic T lymphocytes), (D) Foxp3 (regulatory T lymphocytes), and (E) GZB (activated cytotoxic T lymphocytes) 
in gastric adenocarcinoma specimens. 
Foxp3, forkhead/winged helix transcription factor; GZB, granzyme B.
Quantification of TILs
An experienced pathologist (SJS) who was blinded to the patient data reviewed the hematoxylin 
and eosin-stained slides for each case. The tumoral center, as well as the centers of four tumor 
quadrants drawn within the borders of each lesion, were analyzed. A representative high-
power field (×400) was chosen for each area and captured as an image. Regions of necrosis or 
hemorrhage were avoided, as were areas of stroma with few tumor glands (less than 10% of 
the total area). The densities of cells with positive reactions to each antibody were calculated 
using ImageJ software (National Institutes of Health, Bethesda, MD, USA). The mean numbers 
of positively stained cells in each area were recorded. Subsequently, the absolute numbers of 
positive cells per high-power field (×400) were calculated for each antigen (CD3, CD4, CD8, 
Foxp3, and GZB) by adding the mean numbers of positive cells in each of the five areas of 
interest (tumoral center and four tumor quadrants) and dividing by five.
Statistical analyses
Age, sex, body mass index, tumor size, circular location, longitudinal location, histologic 
type, lymphovascular invasion (LVI), perineural invasion, T and N classification, and 
stage were evaluated as clinical variables. Categorical data were compared using the χ2 or 
Fisher's exact tests. Absolute numbers of cells positive for each stain and the relative ratio 
between two different stains were compared using the Student's t-test or analysis of variance 
(ANOVA). Median counts were used to divide patients into low- and high-density groups. 
The Kaplan–Meier method was used to construct survival curves, and their differences were 
assessed using the log-rank test. Cox proportional hazard models were applied for univariate 
analysis. The proportionality assumption for the Cox model was evaluated by Schoenfeld 
residuals and Grambsch-Therneau tests. Independent predictors of survival were assessed 
using multivariate Cox forward stepwise regression. Age, sex, and factors with P-values <0.10 
in the univariate analysis were subjected to multivariate analysis. A 2-tailed P-value of 0.05 or 
less was considered statistically significant. All statistical analyses were performed using SAS 
software, version 9.4 (SAS Institute, Cary, NC, USA).
RESULTS
Patient demographics and TILs
Table 1 shows the clinicopathological parameters associated with the subsets of TILs stained 
with monoclonal antibodies against CD3, CD4, CD8, Foxp3, and GZB (Fig. 1). The density 
of CD3+ cells was higher in undifferentiated histologic-type tumors (P=0.038), whereas 
CD4+ cell density was higher in early stage lesions (P=0.027). The density of CD8+ cells 
was significantly higher in men and in tumors with advanced T classification (P=0.038 and 
P=0.044, respectively). Foxp3+ cell density was significantly higher in patients who were 
negative for perineural invasion (P=0.001), whereas GZB+ levels were significantly lower in 
patients with small tumor sizes (P=0.024) and early T classification (P<0.001).
Tumor location and TILs
The associations between the anatomic locations of the tumors and TIL subsets are 
shown in Fig. 2. While levels of CD3+ and CD4+ cells were not associated with longitudinal 
locations, CD8+ cell densities were significantly lower in cardia cancers (Fig. 2A). The 
densities of Foxp3+ and GZB+ cells were also significantly higher in cardia cancers than in 
tumors located elsewhere. No association was found among circular locations and the 
distribution of TILs (Fig. 2B).
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Table 1. Clinical parameters and TILs
Characteristics Subsets of TILs
Number CD3 P-value CD4 P-value CD8 P-value Foxp3 P-value GZB P-value
Age (yr) 0.284 0.645 0.779 0.265 0.912
<60 272 (50.2%) 172±64.8 96.8±50.1 80.2±41.4 18.7±15 20.3±17.7
≥60 270 (49.8%) 166.2±59.5 94.9±48.8 81.1±36.7 20.2±15.7 20.5±17
Sex 0.119 0.844 0.038 0.898 0.484
Male 347 (64.0%) 166±60.3 96.2±51.1 83.3±39.7 19.5±15.3 20.8±17
Female 195 (36.0%) 174.7±65.2 95.3±46.5 76±37.7 19.4±15.5 19.6±18
Body mass index (kg/m2) 0.869 0.603 0.284 0.264 0.587
Low 271 (50.0%) 168.7±61.9 96.9±51.4 78.8±39.2 20.2±17.8 20±15.2
High 271 (50.0%) 169.5±62.6 94.7±47.4 82.4±39 18.7±12.4 20.8±19.1
Tumor size (>4 cm) 0.769 0.251 0.166 0.718 0.024
No 268 (49.4%) 168.3±62.9 98.3±50.5 78.3±35.8 19.2±16.9 18.7±15.5
Yes 274 (50.6%) 169.9±61.6 93.4±48.4 82.9±42 19.7±13.7 22.1±18.8
Histologic type* 0.038 0.240 0.115 0.177 0.598
Differentiated 217 (40.0%) 162.3±61.1 92.8±48.8 77.5±33.8 20.6±16.9 19.9±16.2
Undifferentiated 325 (60.0%) 173.6±62.6 97.9±49.8 82.7±42.2 18.7±14.1 20.7±18.1
LVI† 0.544 0.699 0.887 0.095 0.477
No 162 (29.9%) 171.3±58.1 99.2±45.9 81.5±39.3 17.3±9.7 17.5±15.7
Yes 205 (37.8%) 174.9±54.6 101.2±52 82.1±35.4 15.7±8.8 18.8±16.6
Perineural invasion† 0.906 0.709 0.844 0.001 0.515
No 203 (37.5%) 175.2±54.5 101.6±48.6 82.3±35.7 17.7±9.8 17±13.2
Yes 144 (26.6%) 174.5±53.9 103.6±50.5 81.5±37.7 14.6±7.9 18.3±18.3
T classification 0.087 0.931 0.044 0.166 <0.001
T1, T2 211 (38.9%) 163.4±60.2 96.1±45.7 76.4±35.3 18.4±14.2 17.4±13.3
T3, T4 331 (61.1%) 172.8±63.3 95.7±51.7 83.4±41.2 20.2±16 22.5±19.4
N classification 0.436 0.061 0.343 0.064 0.913
N− 256 (47.2%) 166.9±62 100±50 82.3±41.7 20.8±16.9 20.3±17.9
N+ 286 (52.8%) 171.1±62.4 92.1±48.7 79.1±36.7 18.3±13.7 20.5±16.7
Stage 0.827 0.027 0.198 0.050 0.370
I, II 317 (58.5%) 168.6±60.7 99.8±49.2 82.4±41.2 20.5±15.9 19.9±17.3
III, IV 225 (41.5%) 169.8±64.5 90.3±49.4 78.1±35.9 17.9±14.5 21.3±17.3
TIL, tumor-infiltrating lymphocyte; LVI, lymphovascular invasion; Foxp3, forkhead/winged helix transcription factor; GZB, granzyme B.
*Histologic type divided to 2 type: 1) Differentiated: papillary, well-differentiated adenocarcinoma and moderately differentiated adenocarcinoma; 2) 
Undifferentiated: poorly differentiated adenocarcinoma, signet-ring cell carcinoma, mucinous cancer, and other undifferentiated carcinomas. †Patients with 








































Fig. 2. Tumor location and TIL expression. (A) Immune responses according to longitudinal location: cardia tumors were associated with significantly different 
distributions of CD8-, Foxp3-, and GZB-positive TILs. (B) Immune responses according to circular location: no significant associations were noted. 
TIL, tumor-infiltrating lymphocyte; Foxp3, forkhead/winged helix transcription factor; GZB, granzyme B. 
*P<0.05 with Bonferroni correction; †P<0.01 with Bonferroni correction.
Comparison of cardia and non-cardia tumors
Cardia cancers were larger in size, showed more LVI, were more commonly located in the 
lesser curvature of the stomach, and had more advanced T classification and stage than 
non-cardia cancers (Table 2). In terms of immune responses, cardia cancers were strikingly 
different from their non-cardia counterparts. Cardia cancers showed fewer total lymphocytes 
(CD3+; P=0.030) and fewer cytotoxic T lymphocytes (CD8+; P<0.001) than non-cardia 
cancers, with no difference in helper T lymphocyte levels (CD4+; P=0.347). We recorded 
fewer cytotoxic T lymphocytes and an increased number of activated cytotoxic T lymphocytes 
(GZB+; P<0.001) in cardia cancers, findings that are suggestive of immune exhaustion. We 
also noted a greater absolute number of regulatory T lymphocytes (Foxp3+; P<0.001) and a 
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Table 2. Comparison of the characteristics of patients with cardia and non-cardia tumors
Characteristics Cardia (n=207) Non-cardia (n=335) P-value
Age (yr) 0.492
<60 100 (48.3%) 172 (51.3%)
≥60 107 (51.7%) 163 (48.7%)
Sex 0.119
Male 141 (68.1%) 206 (61.5%)
Female 66 (31.9%) 129 (38.5%)
Body mass index (kg/m2) 23.2±3.2 23.1±3.3 0.886
Tumor size (>4 cm) 0.029
No 90 (43.5%) 178 (53.1%)
Yes 117 (56.5%) 157 (46.9%)
Histologic type* 0.068
Differentiated 93 (44.9%) 124 (37.0%)
Undifferentiated 114 (55.1%) 211 (63.0%)
LVI† 0.026
No 38 (35.2%) 124 (47.9%)
Yes 70 (64.8%) 135 (52.1%)
Perineural invasion† 0.151
No 48 (52.2%) 155 (60.8%)
Yes 44 (47.8%) 100 (39.2%)
Circular location‡ 0.031
Lesser curvature 107 (54.6%) 154 (46.5%)
Greater curvature 14 (7.1%) 52 (15.7%)
Anterior wall 29 (14.8%) 49 (14.8%)
Posterior wall 46 (23.5%) 76 (23%)
T classification <0.001
T1, T2 60 (29%) 151 (45.1%)
T3, T4 147 (71%) 184 (54.9%)
N classification 0.130
N0 86 (41.5%) 170 (50.7%)
N1 27 (13%) 45 (13.4%)
N2 39 (18.8%) 45 (13.4%)
N3 55 (26.6%) 75 (22.4%)
Stage <0.001
I, II 103 (49.8%) 214 (63.9%)
III, IV 104 (50.2%) 121 (36.1%)
CD3 161.1±74.3 174±53.0 0.030
CD4 98.7±63.9 94.1±37.9 0.347
CD8 71.9±38.1 86.0±38.8 <0.001
Foxp3 23.2±21 17.2±9.8 <0.001
GZB 29.9±21.5 13.9±9.4 <0.001
Foxp3/CD4 (%) 31.6±30.7 19.6±11.9 <0.001
LVI, lymphovascular invasion; Foxp3, forkhead/winged helix transcription factor; GZB, granzyme B.
*Histologic type divided to 2 type: 1) Differentiated: papillary, well-differentiated adenocarcinoma and moderately 
differentiated adenocarcinoma; 2) Undifferentiated: poorly differentiated adenocarcinoma, signet-ring cell carcinoma, 
mucinous cancer, and other undifferentiated carcinomas. †Patients with missing information (175, lymphovascular 
invasion; 195, perineural invasion) were excluded from the analysis. ‡Circular location unknown (n=15).
stable number of CD4+ T lymphocytes in cardia cancers, resulting in a higher Foxp3+/CD4+ 
ratio (P<0.001) in cardia cancers than in non-cardia cancers.
Prognostic implications of the immune response according to tumor location
High CD3+ and CD4+ cell densities were associated with a good prognosis only in cardia 
cancers (Fig. 3A-D), while a high Foxp3+ cell density was associated with a good prognosis 
only in non-cardia cancers (Fig. 3E and F). Remarkably, a high Foxp3+/CD4+ ratio was 
associated with poor prognosis in cardia cancer patients and with good prognosis in non-
cardia cancer patients (Fig. 3G and H). CD8+ and GZB+ expression was not associated with a 
difference in survival according to tumor location (data not shown).
Univariate Cox regression analysis of overall survival for the entire study cohort revealed 
that total gastrectomy, larger tumor size, advanced T classification, lymph node metastasis, 
and low CD4+ and CD8+ cell densities were poor prognostic factors (Table 3, whole cohort). 
Multivariate analysis showed that total gastrectomy (hazard ratio [HR], 1.75; 95% confidence 
interval [CI], 1.291–2.378), advanced T classification (HR, 1.99; 95% CI, 1.42–2.79), lymph 
node metastasis (HR, 2.31; 95% CI, 1.69–3.14), and low CD8+ cell density (HR, 0.99; 95% CI, 
0.992–0.999) were independent predictors of overall survival.
In the subgroup analysis of cardia cancer (Table 3, cardia only), advanced age (HR, 1.023; 
95% CI, 1.01–1.04), higher T classification (HR, 2.029; 95% CI, 1.11–3.72), lymph node 
metastasis (HR, 3.319; 95% CI, 1.95–5.66), low CD3+ cell density (HR, 0.997; 95% CI, 0.994–
0.999), and a high Foxp3+/CD4+ ratio (HR, 1.007; 95% CI, 1.00–11.012) were independent 
predictors of an unfavorable prognosis. In non-cardia cancer (Table 3, non-cardia only), 
total gastrectomy (HR, 2.147; 95% CI, 1.51–3.06), higher T classification (HR, 2.158; 95% CI, 
1.43–3.27), lymph node metastasis (HR, 1.85; 95% CI, 1.25–2.75), and a low Foxp3+/CD4+ ratio 
(HR, 0.978; 95% CI, 0.96–0.99) were independent predictors of an unfavorable prognosis.
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Table 3. Univariate and multivariate analyses of factors associated with overall survival
Factors Whole cohort (n=542) Cardia (n=207) Non-cardia (n=335)
HR 95% CI P-value HR 95% CI P-value HR 95% CI P-value
Univariate
Age 0.998 0.988–1.008 0.687 1.004 0.988–1.019 0.652 0.994 0.98–1.007 0.350
Sex 1.181 0.906–1.541 0.218 0.837 0.544–1.288 0.419 1.545 1.092–2.188 0.014
Total gastrectomy 2.148 1.589–2.904 <0.001 N/A 2.479 1.747–3.519 <0.001
Tumor size (>4 vs. <4 cm) 2.040 1.559–2.669 <0.001 2.110 1.392–3.197 <0.001 1.974 1.385–2.815 <0.001
T classification (T3/T4 vs.  T1/T2) 2.810 2.057–3.838 <0.001 3.002 1.759–5.125 <0.001 2.676 1.812–3.951 <0.001
N positive vs. negative 3.082 2.312–4.108 <0.001 3.800 2.366–6.103 <0.001 2.603 1.799–3.766 <0.001
CD3 0.998 0.996–1.000 0.109 0.997 0.995–1.000 0.034 1.001 0.997–1.004 0.701
CD4 0.997 0.994–1.000 0.043 0.996 0.992–0.999 0.009 1.001 0.996–1.005 0.763
CD8 0.996 0.992–0.999 0.020 0.996 0.991–1.001 0.160 0.997 0.992–1.001 0.159
Foxp3 0.994 0.985–1.003 0.196 0.998 0.989–1.007 0.700 0.972 0.953–0.992 0.006
GZB 0.998 0.990–1.006 0.628 0.993 0.983–1.002 0.139 0.983 0.961–1.006 0.159
Foxp3/CD4 1.004 0.998–1.009 0.166 1.006 1.000–1.011 0.034 0.974 0.956–0.993 0.007
Multivariate
Age 1.023 1.006–1.040 0.008
Total gastrectomy 1.752 1.291–2.378 <0.001 2.147 1.507–3.059 <0.001
T classification (T3/T4 vs. T1/T2) 1.991 1.419–2.793 <0.001 2.029 1.106–3.721 0.022 2.158 1.425–3.266 <0.001
N positive vs. negative 2.307 1.694–3.142 <0.001 3.319 1.947–5.658 <0.001 1.854 1.250–2.750 0.002
CD3 0.997 0.994–0.999 0.016
CD8 0.995 0.992–0.999 0.010
Foxp3/CD4 1.007 1.001–1.012 0.022 0.978 0.959–0.997 0.022
Forward stepwise elimination with a threshold of P=0.10 was used to select variables for inclusion.
HR, hazard ratio; CI, confidence interval; N/A, not applicable; Foxp3, forkhead/winged helix transcription factor; GZB, granzyme B.
In multivariate analysis of relapse-free survival, immune responses were not associated with 
prognosis. Only T classification and lymph node metastasis were identified as independent 
risk factors for both cardia cancers (HR, 4.57; 95% CI, 2.66–7.86 and HR=3.306; 95% 
197https://jgc-online.org https://doi.org/10.5230/jgc.2020.20.e21













0 24 48 72 96 120 144 168 1920 24 48 72 96 120 144 168 192
0 24 48 72 96 120 144 168 1920 24 48 72 96 120 144 168 192
0 24 48 72 96 120 144 168 1920 24 48 72 96 120 144 168 192


























































































































Fig. 3. Survival according to immune responses in cardia and non-cardia tumors. Kaplan–Meier analysis of overall survival in cardia and non-cardia patients as a 
function of (A, B) CD3 (T lymphocytes), (C, D) CD4 (helper T lymphocytes), and (E, F) Foxp3 (regulatory T lymphocytes) cell densities and (G, H) Foxp3/CD4 ratio. 
High (red) versus low (black) expression groups were divided according to median values. 
TIL, tumor-infiltrating lymphocyte; Foxp3, forkhead/winged helix transcription factor.
CI=2.09–5.23, respectively) and non-cardia cancers (HR, 3.951; 95% CI, 2.23–6.99 and HR, 
3.099; 95% CI, 1.88–5.12, respectively).
DISCUSSION
We previously demonstrated the prognostic significance of Foxp3+/CD4+ ratio in a cohort of 180 
cardia cancer patients [6]. In this study, we accumulated data from additional cardia (n=207) 
and non-cardia (n=335) cancer patients to examine the role of immune cells in gastric cancer. 
Our findings demonstrate that the nature and prognostic significance of the immune response 
differs between cardia and non-cardia cancers. Cardia tumors exhibited lower CD3+ and CD8+ 
cell densities but higher Foxp3+ and GZB+ cell densities than non-cardia tumors. Furthermore, 
we found that a high Foxp3+/CD4+ ratio was associated with a poor prognosis in cardia cancer 
and a favorable prognosis in non-cardia cancer, corroborating our previous findings.
Immune responses that are specific to certain tumor locations within a single organ have also 
been observed in colorectal cancer, in which tumors in the left colon exhibit clinicopathologic 
[22] and molecular [23] characteristics that are distinct from those exhibited by tumors in 
the right colon. A study of the linear distribution of immune cells in normal colons revealed 
that the numbers of CD3+ and CD8+ cells progressively decreased from the ascending colon to 
the rectum [24]. Another recent study comparing cancers in the right colon, left colon, and 
rectum showed that high Foxp3+ cell density was a favorable prognostic factor only in patients 
with rectal tumors [25]. Such findings may also translate to gastric cancer and could explain 
the favorable prognostic effect of Foxp3+ cells in non-cardia cancer.
In general, high infiltration of regulatory (Foxp3+) T lymphocytes is known to be associated 
with a poor prognosis, which is consistent with our data from patients with cardia cancer. 
Paradoxically, colorectal [26,27] and oral cavity [28] cancers, which are expected to have a high 
bacterial burden, demonstrate a favorable prognosis when levels of regulatory T lymphocytes 
are high, indicating that the suppression of inflammation by regulatory cells confers an 
antitumor effect [29,30]. In our study, patients with non-cardia cancers with high regulatory 
T lymphocyte infiltration showed a favorable prognosis. Achlorhydria caused by atrophic 
gastritis and Helicobacter pylori infection results in bacterial overgrowth and dysbiosis in the 
stomach [31]. As such, the infiltration of Foxp3+ TILs might improve a patient's prognosis 
by suppressing inflammation and subsequent carcinogenesis [32-34]. As stated above, 
reduced acidity is an underlying cause of non-cardia cancer while high acidity supports the 
development of cardia cancer [18,19]. These opposing carcinogenic mechanisms may be 
reflected in the contrasting prognostic effects of regulatory T-cells in gastric cancers.
Generally, cytotoxic T-cells (CD8+) are regarded as important prognostic factors in gastric 
cancer [9,12]. In this study, we found that a high CD8+ count was independently associated 
with a favorable prognosis when the data were analyzed as a whole, as shown in Table 3. 
These findings corroborate those of other studies [9,12]. However, a high CD8+ count was 
not significantly associated with prognosis when data for cardia and non-cardia cancers were 
analyzed separately. These results indirectly support the importance of considering tumor 
location in the analyses and interpretation of data for gastric cancer.
This study has some limitations. First, owing to the retrospective nature of the study, there 
may have been bias during patient selection. Second, we did not evaluate the status of  
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H. pylori infection, which could be a confounding factor since it is associated with acidity 
and inflammation. Third, the current findings may not be generalizable to other solid organ 
cancer types. Despite these limitations, we found that gastric tumors exhibit significantly 
divergent characteristics depending on their gastric locations after adjusting for stage and 
other clinicopathological factors [5]. Moreover, to the best of our knowledge, our study is the 
first to investigate differences in immune cell characteristics in gastric cancer according to 
the topographic locations of tumors within the stomach.
In summary, we found that the densities and prognostic effects of TILs differ according to 
the tumor location in the stomach. Most notably, we observed opposing prognostic effects 
associated with a high Foxp3/CD4 ratio between patients with cardia and non-cardia gastric 
cancer. Overall, our study indicates that the longitudinal location of a tumor within the 
stomach should be considered when designing individualized immunotherapy protocols for 
patients with gastric cancer.
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